Amgen's shares posted stellar gains last month. Can this blue chip biotech stock keep churning higher?
News & Analysis: Amgen
Both biotechs are developing revolutionary new cancer drugs, but which stock is better for your portfolio right now?
It’s looking competitive in one cancer drug class.
AMGN earnings call for the period ending September 30, 2019.
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
AbbVie and Amgen are two great stocks that are way too cheap right now.
Appearances can be deceiving.
Doctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.
Which stock wins in a battle between these two big biotechs?
And what they're likely to do with their billions of dollars that could richly reward investors.